文献速递主动脉疾病

采用开窗/分支支架行开放或腔内修复治疗复杂腹主动脉瘤的单中心经验

Single-center experience with complex abdominal aortic aneurysms treated by open or endovascular repair using fenestrated/branched endografts.
PubMed 文献 · J Vasc Surg · 2018-03-03

本单中心回顾性分析纳入2010年1月至2017年2月择期治疗的153例复杂腹主动脉瘤患者(开放修复69例,开窗/分支腔内修复84例),比较两组结局。腔内修复组重症比例和合并症评分更高,但输血需求、主要不良事件、手术时间、估计失血量、ICU及住院时间均低于开放组,30天死亡率无显著差异。作者认为在高危手术患者中应用开窗/分支腔内修复治疗复杂腹主动脉瘤安全有效,短期结果与低危开放修复患者相当。

要点

  • 开窗/分支腔内修复组主要不良事件40.6% vs 开放组13.1%,开放组更高(P < .001)。
  • 开窗/分支腔内修复组输血需求1.2% vs 开放组100%,开放组更高(P < .001)。
  • 两组30天死亡率2.9% vs 2.4%,差异无统计学意义(P = .84)。

核心结论

  • 作者认为,该真实世界经验提示在高危手术患者中使用开窗/分支腔内修复治疗复杂腹主动脉瘤安全有效,短期结果与接受开放修复的低危患者相当。
  • 接受开窗/分支腔内修复的患者ICU和住院时间更短、主要不良事件更少、恢复更快。
  • 随着经验积累,开窗/分支腔内修复的手术时间和辐射剂量下降,即使病例复杂度增加。

研究设计与样本

  • 单中心回顾性分析,连续纳入2010年1月至2017年2月择期接受开放修复或开窗/分支腔内修复的复杂腹主动脉瘤患者。
  • 共153例患者,其中开放修复组69例,开窗/分支腔内修复组84例。

主要发现

  • 开窗/分支腔内修复组男性64例、平均年龄75.8 ± 7.6岁;开放修复组男性55例、平均年龄71.2 ± 7.9岁。
  • 开窗/分支腔内修复组美国麻醉医师协会3级和4级比例为60% vs 开放修复组0%(P < .001),血管外科学会/美国血管外科学会合并症严重度评分中位数15 vs 7(P < .001)。
  • 开窗/分支腔内修复组共 targeting 235根血管,技术成功率97.6%;开放修复组31例需同期肾动脉血运重建。
  • 开放修复组相比开窗/分支腔内修复组:输血需求100% vs 1.2%、主要不良事件40.6% vs 13.1%、手术时间304分钟 vs 140分钟、估计失血量2246 mL vs 165 mL、ICU住院时间3天 vs 1天、住院时间7天 vs 2天,均更高(P < .001)。
  • 30天死亡率开放修复组2.9% vs 开窗/分支腔内修复组2.4%(P = .84);腹腔干上阻断位置与术后肾功能不全发生率增加相关;开窗/分支腔内修复组出院回家比例97.6% vs 开放修复组59.4%(P < .001)。

关键数值与推荐

  • 平均随访31个月(开窗/分支腔内修复组17个月,开放修复组48个月),二次干预率开窗/分支腔内修复组3.7% vs 开放修复组5.8%(P = NS)。
  • 分支不稳定免于发生率99%(95%CI 96.2%-99.8%),再干预免于发生率96%(95%CI 87.1%-98.6%)。

临床怎么用

  • 作者认为,在高危手术患者中采用开窗/分支腔内修复治疗复杂腹主动脉瘤安全有效,短期结果与低危开放修复患者相当。
  • 接受开窗/分支腔内修复的患者ICU和住院时间更短、主要不良事件更少、恢复更快。
  • 随着经验积累,开窗/分支腔内修复的手术时间和辐射剂量下降,即使病例复杂度增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to evaluate outcomes of patients with complex abdominal aortic aneurysms (cAAAs) treated with open repair (OR) or fenestrated/branched endovascular aneurysm repair (F/B-EVAR) from a single center. METHODS: A retrospective analysis of consecutive patients with cAAAs treated electively by OR or F/B-EVAR between January 2010 and February 2017 was conducted. Demographics of the patients, cardiovascular risk factors, procedure time, number of vessels incorporated, radiation dose, estimated blood loss, intensive care unit (ICU) length of stay (LOS), and hospital LOS were recorded. End points included target vessel patency, aneurysm rupture, freedom from reintervention, and major adverse events (MAEs). RESULTS: During this period, 153 patients (OR, 69; F/B-EVAR, 84) underwent repair of cAAA. The majority were male (OR, 55; F/B-EVAR, 64), with a mean age of 75.8 ± 7.6 years (F/B-EVAR) and 71.2 ± 7.9 years (OR). Patients in the F/B-EVAR group were more likely to be American Society of Anesthesiologists class 3 and 4 (60% vs 0%; P < .001) and had a higher median Society for Vascular Surgery/American Association for Vascular Surgery comorbidity severity score (15 vs 7; P < .001). A total of 235 vessels were targeted in the F/B-EVAR group, with a technical success of 97.6%. Thirty-one patients in the OR group required concomitant renal artery revascularization. Transfusion requirements (100% vs 1.2%), MAEs (40.6% vs 13.1%), procedure length (304 minutes vs 140 minutes), estimated blood loss (2246 mL vs 165 mL), ICU LOS (3 days vs 1 day), and hospital LOS (7 days vs 2 days) were higher (P < .001) in the OR group compared with the F/B-EVAR group. The 30-day mortality was 2.9% and 2.4% (P = .84) in the OR group and F/B-EVAR group, respectively. Supraceliac clamp site was associated with increased incidence of postoperative renal insufficiency. A decrease in procedure time, contrast volume, fluoroscopy time, and fluoroscopy dose was noted in the F/B-EVAR group with increasing experience even as case complexity increased. More patients were discharged home after F/B-EVAR (97.6% vs 59.4%; P < .001). With a mean follow-up of 31 months (F/B-EVAR, 17 months; OR, 48 months), the rate of secondary intervention was 3.7% and 5.8% (P = NS) for F/B-EVAR and OR, respectively. Freedom from branch instability and reintervention was 99% (95% confidence interval, 96.2%-99.8%) and 96% (95% confidence interval, 87.1%-98.6%), respectively. CONCLUSIONS: Results of this "real-world" experience suggest that the use of F/B-EVAR for the treatment of cAAAs in high-risk surgical patients is safe and effective and has comparable short-term results to those of low-risk patients undergoing OR. Patients treated by F/B-EVAR had shorter ICU and hospital LOS, lower MAEs, and faster convalescence. A decrease in procedure time and radiation dose was noted as experience was gained, even as complexity increased.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Manunga J, Sullivan T, Garberich R, et al. Single-center experience with complex abdominal aortic aneurysms treated by open or endovascular repair using fenestrated/branched endografts. J Vasc Surg. 2018. PMID: 29510915. doi:10.1016/j.jvs.2017.11.093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。